InvestorsHub Logo
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Wednesday, 08/02/2017 8:02:25 AM

Wednesday, August 02, 2017 8:02:25 AM

Post# of 192
U.S. Orphan Drug tally

Aug. 2, 2017 6:56 AM ET|By: Douglas W. House, SA News Editor
Novartis' (NYSE:NVS) canakinumab (branded as ILARIS) for adult-onset Still's disease, a rare autoimmune disorder characterized by persistent high spiking fevers, joint pain and a salmon-colored bumpy rash.

Kamada's (NASDAQ:KMDA) Glassia [Alpha-1 Proteinase Inhibitor (Human)] for the prevention of graft-versus-host disease.

Roche's (OTCQX:RHHBY) Actemra (tocilizumab) for the treatment of CAR-T cell-induced cytokine release syndrome.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KMDA News